Search

Search results

717 results found

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Alikhan, Ali, Christopher Sayed, Afsaneh Alavi, Raed Alhusayen, Alain Brassard, Craig Burkhart, Karen Crowell, et al. 2019. “North American Clinical Management Guidelines for Hidradenitis Suppurativa: A Publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, Evaluation, and the Use of Complementary and Procedural Management.”. Journal of the American Academy of Dermatology 81 (1): 76-90.

Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10.

Kimball, Alexa B, Tatsuyoshi Kawamura, Krupali Tejura, Carol Boss, Ana R Hancox, Jonathan C Vogel, Seth M Steinberg, Maria L Turner, and Andrew Blauvelt. 2002. “Clinical and Immunologic Assessment of Patients With Psoriasis in a Randomized, Double-Blind, Placebo-Controlled Trial Using Recombinant Human Interleukin 10.”. Archives of Dermatology 138 (10): 1341-6.

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.

Gordon, Kenneth B, Kim A Papp, Richard G Langley, Vincent Ho, Alexa B Kimball, Cynthia Guzzo, Newman Yeilding, et al. 2012. “Long-Term Safety Experience of Ustekinumab in Patients With Moderate to Severe Psoriasis (Part II of II): Results from Analyses of Infections and Malignancy from Pooled Phase II and III Clinical Trials.”. Journal of the American Academy of Dermatology 66 (5): 742-51.